Prestige Consumer Healthcare (NYSE:PBH) Shares Gap Up – Should You Buy?

Prestige Consumer Healthcare Inc. (NYSE:PBH) gapped up prior to trading on Friday . The stock had previously closed at $66.52, but opened at $68.99. Prestige Consumer Healthcare shares last traded at $69.50, with a volume of 15,256 shares trading hands.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Canaccord Genuity Group dropped their price target on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Jefferies Financial Group reduced their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Finally, Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $80.60.

Prestige Consumer Healthcare Stock Performance

The stock has a market cap of $3.27 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 2.09 and a beta of 0.43. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The stock’s 50-day moving average is $64.34 and its 200-day moving average is $63.51.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The company had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same period last year, the firm posted $1.22 earnings per share. The business’s revenue was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the completion of the transaction, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 2,000 shares of company stock worth $125,930. Corporate insiders own 1.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd lifted its stake in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the period. UMB Bank n.a. grew its position in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in Prestige Consumer Healthcare in the 4th quarter worth approximately $29,000. First Horizon Corp acquired a new stake in Prestige Consumer Healthcare during the third quarter worth about $32,000. Finally, Barrow Hanley Mewhinney & Strauss LLC raised its holdings in shares of Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock worth $34,000 after buying an additional 283 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).